NOIDS.wiki
Calculator
Shop Potency Calculator
Cannabis Science

Rimonabant: Specs, Where It Fits & Evidence

Cannabinoid · Pharmaceutical

NoPharmaceuticalCB1 inverse agonistWithdrawn

Rimonabant is a non-intoxicating pharmaceutical CB1 inverse agonist, an anti-obesity CB1 blocker that was withdrawn because of psychiatric side effects.

Full name
Rimonabant
Molecular formula
C22H21Cl3N4O
Class / family
CB1 inverse agonist
Precursor / from
Synthetic
Intoxicating?
No
Research status
Withdrawn

Where it fits

Rimonabant derives from Synthetic. See the Synthetic & altered cannabinoids index for how it relates to the rest of the family.

What the research shows

Rimonabant has withdrawn-level evidence; see the class index and related compounds for cited studies.

CB1 Inverse Agonism, RIO Clinical Trials, and Worldwide Market Withdrawal

Rimonabant (SR141716A; C22H21Cl3N4O) is a synthetic diarylpyrazole derivative that acts as a selective cannabinoid CB1 receptor antagonist and inverse agonist. In the Phase III Rimonabant in Obesity (RIO) randomized controlled trials, 20 mg/day rimonabant significantly reduced body weight, waist circumference, and cardiometabolic risk markers compared with placebo (Van Gaal et al., 2005, The Lancet, PubMed PMID 15836887; Després et al., 2005, New England Journal of Medicine, PubMed PMID 16291982). However, a pooled meta-analysis of 4,105 patients demonstrated that central CB1 blockade significantly increased the incidence of severe depressive disorders, anxiety, and suicidal ideation, leading to FDA rejection in 2007 and European Medicines Agency market suspension in 2008 (Christensen et al., 2007, The Lancet, PubMed PMID 18022033).

FAQ

How does rimonabant act on the CB1 receptor?

Unlike THC, which activates CB1 receptors as a partial agonist, rimonabant (SR141716A) is a selective CB1 antagonist and inverse agonist that blocks endogenous cannabinoid tone and suppresses appetite.

Why was rimonabant (Acomplia) withdrawn from the market?

Although rimonabant produced clinically meaningful weight loss in Phase III trials, it was suspended across Europe in 2008 after clinical trials and post-marketing surveillance revealed a significantly increased risk of severe depression, anxiety, and suicidal ideation.

What did rimonabant teach researchers about the endocannabinoid system?

The psychiatric adverse events caused by brain-penetrant CB1 blockade demonstrated that basal central endocannabinoid tone is essential for mood regulation and emotional homeostasis.

Part of the NOIDS cannabinoids index. Educational reference, not medical advice.

This article is for educational purposes only. Always follow local laws regarding cannabis preparation and use.

Scroll to Top